Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
Janssen, the pharmaceutical branch of Johnson and Johnson, knew that a point-of-care device used for measuring international normalized ratio was giving falsely low readings during the ROCKET AF trial, a BMJ investigation finds.
In ROCKET AF, published in the New England Journal of Medicine in 2011, the oral anticoagulant rivaroxaban was associated with less intracranial and fatal bleeding compared with warfarin in patients with atrial fibrillation. The trial's findings, which led to rivaroxaban's approval, have since come under scrutiny — in part because the INRatio device was later recalled over its poor accuracy. (INRatio's misleading results, some say, may have made rivaroxaban seem safer than warfarin.)
Now The BMJ reports that Janssen withheld its knowledge of the device's poor performance from the trial's data safety monitoring board and from the FDA prior to rivaroxaban's approval.
For now, the jury is out on whether ROCKET AF's results can be trusted, the report says. The FDA is conducting its own safety investigation, which includes using electronic health records to compare rivaroxaban and warfarin.
Comment
LINK(S):
The BMJ investigation (Free)
The BMJ editorial (Subscription required)
Background: Prior Physician's First Watch coverage of ROCKET AF controversy (Free)